Short answer
Aldeyra Therapeutics, Inc. (ALDX) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$5M
- +44.2% YoY · −57.9% QoQ
- EPS (diluted)
- −$0.09
- +43.8% YoY · −50.0% QoQ
Source: XBRL data from the Aldeyra Therapeutics, Inc. (ALDX) Q2 2026 10-Q on SEC EDGAR. USD.
Aldeyra Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $0; no products approved for sale
- Net loss $5.5M vs $9.8M YoY; operating loss $5.9M vs $10.2M
- R&D expense $3.5M vs $8.5M YoY; late-stage candidates 20% of quarterly R&D
- Cash and equivalents $45.1M at June 30, 2026; no debt after repaying $15.0M principal
- Outlook: operating losses expected; AbbVie option unexercised as of August 6, 2026
Risk Factors
- Newly added FDA transparency risk, triggered by 2025 policy requiring prompt public release of future Complete Response Letters
- Reproxalap approval risk materially elevated after the March 17, 2026 Complete Response Letter citing inconsistent trials and insufficient evidence
- Regulatory risk: FDA may require additional clinical trials before NDA resubmission, increasing costs and delaying potential approval
- Commercial risk: AbbVie may not exercise its exclusive option, leaving Aldeyra responsible for reproxalap development and commercialization funding
- Financial risk: continued reproxalap development may require additional capital unavailable on acceptable terms
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Aldeyra Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.